Marcel M. Verbeek

Marcel M. Verbeek

Auto-generated profile, based on publicly available information

Marcel M. Verbeek

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Netherlands

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2015 in JAMA
Verified
Journal Article
Open access
PDF file
WJWillemijn J. Jansen
Willemijn J. Jansen
RORik Ossenkoppele
Rik Ossenkoppele
DKDirk L. Knol
Dirk L. Knol
BTBetty Tijms
Betty Tijms
PSPhilip Scheltens
Philip Scheltens
HZHenrik Zetterberg
Henrik Zetterberg
Alzheimer disease (AD) is the most common cause of dementia, with a worldwide prevalence of about 25 million in 2010, expected to be doubled by 2030 because of increased life expectancy.1 The earliest recognizable pathological event in AD is cerebral amyloid-β aggregation.2 This pathology may be present up to 20 years before the onset of dementia.3,4 Novel research criteria for AD in individuals without dementia emphasize the presence of amyloid pathology to define the first stage of the disease.5,6

19 August 2015 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
UAUlf Andreasson
Ulf Andreasson
APArmand Perret-Liaudet
Armand Perret-Liaudet
LDLinda J. C. van Waalwijk van Doorn
Linda J. C. van Waalwijk van Doorn
KBKaj Blennow
Kaj Blennow
DCDavide Chiasserini
Davide Chiasserini
CTCharlotte E. Teunissen
Charlotte E. Teunissen
Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer’s disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of low-abundance biomarkers. However, the quality of ELISA methods varies, which may introduce both systematic and random errors. This urges the need for more rigorous control of assay performance, regardless of its use in a research setting, in clinical routine, or drug development. The aim of a method validation is to present objective evidence that a method fulfills the requirements for its intended use. Although much has been published on which parameters to investigate in a method validation, less is available on a detailed level on how to perform the corresponding experiments. To remedy this, standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results. Even though the SOPs were developed with the intended use for immunochemical methods and to be used for multicenter evaluations, most of them are generic and can be used for other technologies as well.

1 August 2014 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
SOSharon Ooms
Sharon Ooms
SOSebastiaan Overeem
Sebastiaan Overeem
KBKees Besse
Kees Besse
MRMarcel Olde Rikkert
Marcel Olde Rikkert
MVMarcel Verbeek
Marcel Verbeek
JCJurgen A. H. R. Claassen
Jurgen A. H. R. Claassen
Research from JAMA Neurology — Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men — A Randomized Clinical Trial

1 May 2013 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
NMNiklas Mattsson
Niklas Mattsson
UAUlf Andreasson
Ulf Andreasson
SPStaffan Persson
Staffan Persson
MCMaria C. Carrillo
Maria C. Carrillo
SCSteven Collins
Steven Collins
MWManfred Windisch
Manfred Windisch

31 May 2021 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
LJLieke Jäkel
Lieke Jäkel
AKAnna M. De Kort
Anna M. De Kort
CKCatharina J.M. Klijn
Catharina J.M. Klijn
FSFloris H.B.M. Schreuder
Floris H.B.M. Schreuder
MVMarcel M. Verbeek
Marcel M. Verbeek
Reported prevalence estimates of sporadic cerebral amyloid angiopathy (CAA) vary widely. CAA is associated with cognitive dysfunction and intracerebral hemorrhage, and linked to immunotherapy‐related side‐effects in Alzheimer's disease (AD). Given ongoing efforts to develop AD immunotherapy, accurate estimates of CAA prevalence are important. CAA can be diagnosed neuropathologically or during life using MRI markers including strictly lobar microbleeds. In this meta‐analysis of 170 studies including over 73,000 subjects, we show that in patients with AD, CAA prevalence based on pathology (48%) is twice that based on presence of strictly lobar cerebral microbleeds (22%); in the general population this difference is three‐fold (23% vs 7%). Both methods yield similar estimated prevalences of CAA in cognitively normal elderly (5% to 7%), in patients with intracerebral hemorrhage (19% to 24%), and in patients with lobar intracerebral hemorrhage (50% to 57%). However, we observed large heterogeneity among neuropathology and MRI protocols, which calls for standardized assessment and reporting of CAA.

27 October 2017 in The World Journal of Biological Psychiatry
Verified
Journal Article
Open access
PLPiotr Lewczuk
Piotr Lewczuk
RPRiederer Peter
Riederer Peter
OEO'Bryant Sid E
O'Bryant Sid E
VMVerbeek Marcel M
Verbeek Marcel M
DBDubois Bruno
Dubois Bruno
JKJohannes Konrhuber
Johannes Konrhuber
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.